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ABSTRACT Fungal infections are a major contributor to infectious disease-related
deaths worldwide. Recently, global emergence of the fungal pathogen Candida auris
has caused considerable concern because most C. auris isolates are resistant to flu-
conazole, the most commonly administered antifungal, and some isolates are resis-
tant to drugs from all three major antifungal classes. To identify novel agents with
bioactivity against C. auris, we screened 2,454 compounds from a diversity-oriented
synthesis collection. Of the five hits identified, most shared a common rocaglate
core structure and displayed fungicidal activity against C. auris. These rocaglate hits
inhibited translation in C. auris but not in its pathogenic relative Candida albicans.
Species specificity was contingent on variation at a single amino acid residue in Tif1,
a fungal member of the eukaryotic initiation factor 4A (eIF4A) family of translation
initiation factors known to be targeted by rocaglates. Rocaglate-mediated inhibition
of translation in C. auris activated a cell death program characterized by loss of mi-
tochondrial membrane potential, increased caspase-like activity, and disrupted vacu-
olar homeostasis. In a rocaglate-sensitized C. albicans mutant engineered to express
translation initiation factor 1 (Tif1) with the variant amino acid that we had identi-
fied in C. auris, translation was inhibited but no programmed cell death phenotypes
were observed. This surprising finding suggests divergence between these related
fungal pathogens in their pathways of cellular responses to translation inhibition.
From a therapeutic perspective, the chemical biology that we have uncovered re-
veals species-specific vulnerability in C. auris and identifies a promising target for de-
velopment of new, mechanistically distinct antifungals in the battle against this
emerging pathogen.
IMPORTANCE Emergence of the fungal pathogen Candida auris has ignited intrigue
and alarm within the medical community and the public at large. This pathogen is
unusually resistant to antifungals, threatening to overwhelm current management
options. By screening a library of structurally diverse molecules, we found that C. au-
ris is surprisingly sensitive to translation inhibition by a class of compounds known
as rocaglates (also known as flavaglines). Despite the high level of conservation
across fungi in their protein synthesis machinery, these compounds inhibited transla-
tion initiation and activated a cell death program in C. auris but not in its relative
Candida albicans. Our findings highlight a surprising divergence across the cell death
programs operating in Candida species and underscore the need to understand the
specific biology of a pathogen in attempting to develop more-effective treatments
against it.
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Over the past decade, Candida auris has emerged as a critical threat to our mostvulnerable populations, captivating researchers, health care workers, and the
media with its environmental persistence, puzzling evolutionary history, and unprece-
dented resistance to the three major antifungal drug classes: azoles, echinocandins, and
polyenes (1, 2). With the pervasiveness of multidrug resistance, the Centers for Disease
Control and Prevention classified C. auris at the most serious threat level (3). Genetic
modifications associated with resistance include those that modify the drug target,
activate drug efflux, or influence resistance mechanisms that remain enigmatic (2, 4–7).
Beyond multidrug resistance, the threat posed by C. auris is exacerbated by the
pathogen’s ability to persist on abiotic surfaces. This issue is critical in hospital settings
where C. auris has been detected on surfaces despite antiseptic treatment, leading to
high transmissibility (8–10). Since the discovery of C. auris in 2009, it has been identified
across the globe, clustering into four major clades, which are both evolutionarily and
geographically distinguishable (5). While recent research efforts have begun to explore
the many questions surrounding C. auris, our understanding of the mechanisms
governing drug resistance and virulence of this organism remains in its infancy.
A powerful strategy to identify pathogen vulnerabilities that could be exploited
therapeutically involves screening compound libraries to identify novel, bioactive
chemical matter. Bioactive molecules can then be used as probes for basic biological
characterization of the organism and as a foundation for development of therapeutic
strategies. Examples of the compounds that have emerged from such screening
endeavors include iKIX1, which abrogates azole resistance in Candida glabrata (11);
F901318, which inhibits pyrimidine biosynthesis in Aspergillus fumigatus (12); and the
indazole derivative Inz-5, which enhances azole activity against Candida albicans (13).
In all cases, analyses of these compounds either defined how drug resistance mediators
could be targeted to mitigate resistance or identified fungus-specific targets that could
be exploited for antifungal drug development. Further, these and other studies high-
lighted the principle that compounds which trigger fungal cell death as opposed to
exerting fungistatic activity provide a therapeutic advantage because they reduce the
likelihood that resistance will emerge (14).
Several distinct types of cell death have been reported in fungi, including necrosis,
autophagy, and apoptosis (15, 16). Necrosis occurs in response to acute chemical or
mechanical damage to the cell, whereas autophagy and apoptosis involve pro-
grammed cellular execution. In some fungal species, autophagy is induced as an
essential component of pathogenesis (17, 18) or upon nutrient starvation (18, 19).
Indeed, prolonged starvation leads to a form of cell death that is dependent on the
expression of specific autophagic proteins and proteases (18, 19). Finally, although the
topic of apoptosis in a single-celled organism remains controversial, multiple reports
have described apoptosis-like responses in fungal species. For example, deletion of cell
cycle genes such as CDC48 (20), expression of mammalian proapoptotic markers such
as Bax (21), or treatment with H2O2 (22) or amphotericin B (23, 24) was shown to lead
to phenotypes characteristic of apoptotic cell death. These include membrane disrup-
tion and phosphatidylserine exposure, nucleosomal DNA fragmentation, calcium influx,
increased levels of reactive oxygen species (ROS), and mitochondrial depolarization (15,
16). While the genetic program(s) responsible for these phenotypes has yet to be
established, these phenotypic observations suggest that particular cellular stresses
induce active forms of cell death with characteristics similar to those seen with
apoptosis in metazoans.
In this study, we screened a diversity-oriented synthetic library, including a subset
of natural-product-inspired compounds, to identify novel probes with antifungal activ-
ity against C. auris. Among 2,454 compounds screened, the majority of bioactive hits
were natural and synthetic variants of the natural-product chemotypes known as
rocaglates, which are well-described inhibitors of translation initiation in mammalian
cells and Saccharomyces cerevisiae (25). We established that the rocaglates inhibit
translation initiation in C. auris, leading to activation of a cell death program with
phenotypic characteristics shared with apoptosis in metazoans. In contrast, the related
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pathogen C. albicans showed inherent resistance to the rocaglates due to an amino
acid variant in the drug-binding domain of translation initiation factor 1 (Tif1), the direct
target of the compound class. When the species was sensitized through the use of a
single TIF1 point mutation, the rocaglates inhibited C. albicans translation but did not
induce cell death. Furthermore, rocaglate-mediated translation inhibition led to hyper-
acidification and fragmentation of the vacuolar compartment, mitochondrial depolar-
ization, and increased caspase-like activity in C. auris but not in the rocaglate-sensitized
C. albicans strain. Our surprising finding that rocaglate-mediated translation inhibition
induces cell death in C. auris but not in C. albicans reveals evolutionary divergence in
fungal responses to translation inhibition and an actionable vulnerability in an emerg-
ing fungal pathogen that poses an urgent threat to human health.
RESULTS
Rocaglates exhibit potent single-agent activity against the emerging pathogen
C. auris. To identify novel chemical probes with bioactivity against C. auris, we screened
molecules in the Boston University Center for Molecular Discovery (BU-CMD) com-
pound library. This library contained 2,454 molecules obtained through diversity-
oriented synthesis techniques as well as semisynthetic natural-product analogs to
encompass greater structural diversity and complexity than conventional combinatorial
chemistry libraries (26). We screened the BU-CMD library at 50 M against C. auris, with
bioactivity defined by percent growth inhibition for each compound compared to
solvent controls. Five hit compounds were identified as inhibiting growth by at least
60% relative to solvent controls (Fig. 1A). The relative potencies of hits from the initial
screen were determined by dose-response assays, which confirmed bioactivity for all hit
compounds (Fig. 1B). When the chemical structures were assessed, the four most
potent hit compounds all shared the cyclopenta[b]benzofuran core found in the
chemical class consisting of rocaglates (Fig. 1C). The two most potent rocaglates,
namely, the natural product CMLD010853 [(-)-methyl rocaglate] (27) and the synthetic
rocaglate analogue CMLD010515 [(-)-RHT] (28), are well-studied translation inhibitors,
and each displayed antifungal activity against C. auris at concentrations below 12.5 M.
Thus, rocaglates display potent antifungal activity against C. auris.
An alarming characteristic of C. auris is its rapid acquisition of resistance to xeno-
biotics, particularly to the fungistatic azole fluconazole (5). Compounds with a fungi-
static mode of action are often unable to eradicate microbial populations and exert
strong selective pressure for the evolution of drug resistance (14). To determine if
screening hits had fungistatic or fungicidal activity against C. auris, we used tandem
assays consisting of antifungal susceptibility testing followed by spotting onto rich
medium without inhibitor. While all of the hit compounds reduced the growth of C.
auris after 48 h, only the four rocaglate compounds exhibited cidal activity (Fig. 1D). As
the rocaglates displayed such promising activity against C. auris, we next assessed their
activity against a range of fungal pathogens, as antifungal activity has been reported
previously against plant fungal pathogens (29). Dose-response assays were performed
against nine human fungal pathogens ordered by their rough phylogenetic distance
from C. auris, followed by spotting assays to evaluate cidality (Fig. 1E). CMLD010515 had
reduced bioactivity against fungal pathogens closely related to C. auris, such as Candida
haemulonii and C. duobushaemulonii, but no antifungal activity against the majority of
more distantly related species. One exception was S. cerevisiae, for which the rocaglate
did have fungicidal activity (Fig. 1E), consistent with previous reports for this chemo-
type (30). These results demonstrate species specificity in rocaglate antifungal activity.
The rocaglates target the translation initiation factor eIF4A in C. auris. Roca-
glates have been reported to inhibit translation initiation in mammalian cells and S.
cerevisiae through interaction with orthologues of the eukaryotic initiation factor 4A
(eIF4A) (30–33). In examining the rocaglates present in the BU-CMD collection, we
found that all four hit rocaglates are among the strongest enhancers of human
eIF4A1-polypurine RNA clamping (34), further supporting the identification of transla-
tion as a putative target. To determine if the rocaglates identified in our screen inhibit
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translation in C. auris, we used a fluorescence-based translation assay. When translation
is unhindered, an alkynylated methionine analog is incorporated into newly translated
proteins, yielding readily detected fluorescent signal upon Click reaction with a green
fluorescent (GF) azide (35). Control-treated C. auris cells displayed strong green fluo-
FIG 1 A screen of the BU-CMD library identified rocaglates as having cidal activity against C. auris. (A) The BU-CMD library was screened at 50 M in RPMI
medium at 30°C for 48 h. Five hits (shown in red) were defined as having inhibited growth of C. auris by 60% compared to a DMSO control. (B) The C. auris
potency of each hit compound was determined by a dose-response assay in which the titer of each compound was determined at a 2-fold dilution in RPMI
medium (x axis). Growth was determined by analysis of the optical density at 600 nm (OD600) in each well and normalized to that of the DMSO control for each
titration (see color bar). Rocaglate compounds are indicated with bold font. (C) Chemical structures of each of the four rocaglates identified from the screen.
(D) Growth of C. auris in the absence and presence of the five hit BU-CMD compounds (top panel). Growth was normalized as described for panel B (see color
bar). The bottom panel shows the corresponding growth seen when 5 l of culture from the well was spotted onto YPD agar without drug and incubated for
24 h. (E) Dose-response assays were used to determine the efficacy of one rocaglate compound (CMLD010515) against several fungal pathogens. The titer of
the compound was determined at a 2-fold dilution in YPD medium (x axis), and the level of growth was measured after 48 h as described above by the use
of both normalized OD600 assays (left) and spotting assays (right).
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rescence, whereas cultures treated with the known translation inhibitor cycloheximide
did not (Fig. 2A). Treatment with each of our rocaglate hits blocked translation as
evidenced by loss of fluorescent signal (Fig. 2A; see also Fig. S1A in the supplemental
material), supporting the conclusion that these rocaglates inhibit translation in C. auris.
To further support the idea that the rocaglates inhibit translation, we performed a
dose-response matrix (checkerboard) consisting of a gradient of rocaglate in combina-
tion with a gradient of another translation initiation inhibitor, 4EGI-1, as combinations
of two compounds targeting the same pathway often elicit additive effects (36). Indeed,
these compounds displayed an additive interaction in terms of both the fractional
inhibitory concentration index at 90% growth inhibition (FICI90) (0.625) and cidality
(Fig. 2B). Finally, to determine in an unbiased manner whether the rocaglates inhibit
translation initiation through binding to eIF4A, we performed experiments with a
drug-sensitized C. auris strain to select for resistance mutations. This strain had the
efflux pump gene CDR1 deleted, allowing lower concentrations of compound to be
used (Fig. S1B). Resistant mutants were assessed for their degree of rocaglate resistance
to CMLD010853 (methyl rocaglate; Fig. 2C) and for cross-resistance to fluconazole by
FIG 2 The rocaglates inhibit translation and target the initiation factor eIF4A in C. auris. (A) A Click-iT protein synthesis
assay kit was used to visualize protein translation. Cells were subcultured and then treated for 10 min with 10 g/ml of
the translation inhibitor cycloheximide or a 50 M concentration of each rocaglate identified from the screen, as indicated.
The L-homopropargylglycine (HPG) alkyne methionine analog was added, and then the cells were fixed. The azide
fluorophore was added, and cells were imaged on the GFP channel to detect if translation had occurred. (B) A
dose-response matrix was used to show the interaction between two compounds. The titer of an eIF4G inhibitor, 4EG1-1,
was determined in a 2-fold dilution (y axis), and that of the rocaglate compound CMLD010515 was determined as indicated
on the x axis. Cells were grown in YPD medium for 48 h, and growth was measured by determination of the optical density
at 600 nm. Growth was normalized to that of the no-drug control (see color bar). The fractional inhibitory concentration
index at 90% growth inhibition (FICI90) was calculated, with values between 0.5 and 1 indicating an additive interaction.
Cells were taken from the checkerboard plate, and 0.5 l was spotted onto YPD agar medium without drug. Plates were
incubated at 30°C for 24 h and imaged. (C) A C. auris-sensitized (cdr1 Δ) strain was used to select for resistant mutants on
YPD agar plates containing a 10 M concentration of the rocaglate compound. The degree of resistance of C. aurismutants
was assessed in YPD medium by dose-response analysis performed with CMLD010853. Growth was determined as
described for panel B. Sanger sequencing of eIF4A was used to confirm mutations in the gene for all resistant isolates
shown (the identified amino acid substitutions are indicated for each strain).
Rocaglates Induce Cell Death in Candida auris ®
March/April 2020 Volume 11 Issue 2 e03329-19 mbio.asm.org 5
dose-response assays in order to eliminate strains likely harboring mutations conferring
enhanced multidrug efflux (Fig. S1C). Sanger sequencing of the EIF4A homolog in C.
auris identified mutations in EIF4a in all independently derived resistant lineages
(Fig. 2C). Thus, the rocaglates operate through their canonical mechanism of translation
initiation inhibition in C. auris by binding to eIF4A.
Rocaglate species specificity is governed by variation in the target binding
pocket. During characterization of the rocaglates, we noted a lack of bioactivity against
many fungal pathogens, including C. albicans (Fig. 1E), and hypothesized the species-
specific activity could be due to alterations in the proximal drug target eIF4A, anno-
tated as translation initiation factor 1 (Tif1) in C. albicans. Clustal omega was used to
align the known target in Homo sapiens (37) and S. cerevisiae (30) to the homologous
sequences in C. auris, C. albicans, and the other fungal pathogens assessed as described
in the Fig. 1E legend (Fig. S2). We focused on the six residues for which mutation has
been reported to confer rocaglate resistance in S. cerevisiae (30) and noted that C.
albicans and closely related species (C. tropicalis, C. dubliniensis, and C. lusitaniae)
contained an alternative residue at position 153 whereas all the sensitive species
possessed a phenylalanine at the equivalent position (residue 152 in C. auris; Fig. S2A).
Notably, C. glabrata and C. neoformans possessed a phenylalanine at this position
(Fig. S2A), despite their intrinsic resistance to the rocaglates (Fig. 1E), suggesting that
other factors, including permeability or efflux, may be responsible for the inactivity of
this compound class against those species. Given the genomic plasticity of Candida
species, we examined the sequences of 40 C. albicans isolates and 132 C. auris isolates
available on FungiDB. All 40 C. albicans isolates examined encoded a leucine at position
153 whereas all 132 C. auris isolates encoded a phenylalanine at position 152 (Fig. S2B).
To determine if this residue was sufficient to confer the resistance phenotype, we
generated a C. auris strain expressing eIF4AF152L and a C. albicans strain expressing
Tif1L153F, each with the residue-swapped version as the sole source of eIF4A, and
monitored translation using the fluorescent translation assay described in the Fig. 2
legend. As predicted, the C. auris eIF4AF152L strain was resistant to rocaglate-mediated
repression of translation, as indicated by green fluorescence, despite the presence of
CMLD010515, while translation in the parental C. auris strain was blocked by the
rocaglate (Fig. 3A). In contrast, the C. albicans Tif1L153F strain was sensitive to rocaglate-
mediated translation inhibition, whereas the C. albicans wild-type strain was resistant,
with persistent translation in the presence of compound (Fig. 3A). These results are
supported by previous studies performed with human eIF4a, which demonstrated that
substitutions of this single amino acid preclude rocaglate engagement with the protein
(32). Thus, the amino acid at residue 153 is responsible for the species specificity of
rocaglate activity.
To determine whether sensitivity to rocaglates in our residue-swapped strains
correlated with a cidal mode of action, dose-response assays were performed, followed
by spotting of cells onto drug-free medium (Fig. 3B). Surprisingly, the sensitized C.
albicans Tif1L153F strain was not killed by exposure to rocaglate (Fig. 3B). To verify that
cell death upon CMLD010515 treatment occurred only in C. auris and not in the
sensitized C. albicans Tif1L153F cells, we stained with propidium iodide, which is
excluded by live cells. Only the sensitive C. auris strain treated with CMLD010515
displayed propidium iodide positivity (Fig. 3C). Thus, even when translation and growth
were inhibited to comparable extents, the rocaglates induced cell death only in C. auris
and not in C. albicans.
Rocaglate treatment disrupts vacuolar homeostasis in C. auris. Next, we sought
to characterize the species-selective cell death phenotype that we had observed. To do
so, we turned to S. cerevisiae, as this species exhibited the same cidal response to
rocaglate exposure as was observed with C. auris (Fig. 1E). We examined a previously
reported S. cerevisiae haploinsufficiency (HIP) profile generated with rocaglamide A, a
structurally related rocaglate (30). HIP is based on the principle that reduced dosage of
a gene encoding a compound’s target or a component of buffering pathways results in
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FIG 3 C. albicans is resistant to the rocaglates due to an altered amino acid in Tif1. (A) A Click-iT protein synthesis assay kit was
used to visualize protein translation upon rocaglate treatment for rocaglate-sensitive and rocaglate-resistant C. auris and C.
(Continued on next page)
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hypersensitivity to that compound (38–40). In addition to confirming that strains
heterozygous for components of the translation initiation complex were hypersensitive
to rocaglate treatment (30), the rocaglamide A HIP profile revealed that the most
hypersensitive strain was heterozygous for VOA1 (30). Voa1 is involved in assembly of
the V-ATPase proton pump that maintains an acidic pH within the vacuole (41).
By assessing growth of the S. cerevisiae VOA1/voa1 mutant in the presence of
CMLD010515, we confirmed that it was hypersensitive to the rocaglate, as were other
strains heterozygous for components of the V0 sector of the V-ATPase or accessory
proteins (P value of 0.05; Fig. 4A).
On the basis of these findings, we hypothesized that as a consequence of translation
inhibition, the rocaglates alter vacuolar pH, which contributes to their fungicidal
activity. To investigate this in C. auris, we used BCECF-AM, an acidotropic dye which
accumulates in acidic cellular compartments, exhibiting increased fluorescence inten-
sity in response to increased pH (42, 43). We found that C. auris cells displayed
significantly less BCECF-AM staining under conditions of treatment with CMLD010515
than untreated cells; however, the results seen with rocaglate-sensitive C. albicans
Tif1L153F did not show as great a loss in intensity upon treatment (Fig. 4B; see also
Fig. S3A and B). Additionally, we did not observe reduced fluorescence in the rocaglate-
resistant C. auris eIF4AF152L strain, suggesting that the loss of fluorescence was not due
to an off-target effect (Fig. S3A and B).
As a reduction in vacuolar pH negatively regulates vacuolar fusion (44, 45), we
explored the impact of rocaglate treatment on vacuole morphology using the vacuolar
membrane dye FM4-64. We observed a significant increase in the number of cells with
abnormal vacuolar morphology in rocaglate-treated C. auris (P value of 0.005);
however, we saw no significant differences with respect to vacuolar morphology upon
rocaglate treatment of our sensitized C. albicans Tif1L153F strain (Fig. 4C and D). This
abnormal morphology appeared consistent with vacuolar fragmentation, which can
occur when fission homeostasis and fusion homeostasis are disrupted by hyperacidi-
fication of the vacuolar compartment (44). To confirm this phenotype, we used trans-
mission electron microscopy (TEM) to visualize cellular ultrastructures and observed
that rocaglate treatment was associated with vacuolar fragmentation in C. auris but not
in C. albicans Tif1L153F (Fig. 4E).
Given that vacuolar acidification frequently occurs during autophagy (46), we
investigated potential activation of this cell death pathway by rocaglate. Using an
Atg8-GFP (Atg8-green fluorescent protein) strain, we saw no induction of autophagy
upon rocaglate treatment, unlike the response induced by the classical inducer of
autophagy, rapamycin (Fig. S4A). Further, we observed no change in sensitivity to the
rocaglates cidal effects in S. cerevisiae autophagy-defective atg1 or atg9 mutants
(Fig. S4B). Finally, we saw no additive growth inhibitory interaction between the
rocaglates and rapamycin in C. auris (Fig. S4C), an effect we would expect if both
compounds activated autophagy. Therefore, although increased vacuolar acidification
and fragmentation occur in response to translation inhibition in C. auris, autophagy is
not the primary process responsible for rocaglate-induced cell death in this organism.
Rocaglate-induced cell death displays phenotypic hallmarks of apoptosis. Phe-
notypes associated with metazoan apoptosis have been observed in pathogenic fungi
under conditions of exposure to various environmental stresses (22–24). To investigate
whether these phenotypes occur in rocaglate-treated C. auris, we first monitored loss
FIG 3 Legend (Continued)
albicans strains, as indicated. The parental C. auris strain contains a nourseothricin N-acetyl transferase (NAT) marker to match the
eIF4AF152L strain. The assay was performed as described for Fig. 2. (B) The degree of resistance of C. auris and C. albicans strains
was assessed by dose-response assays, as described for Fig. 1 (left panel). Cells were taken from the MIC assays, and 5 l was
spotted onto YPD medium without drug. Plates were incubated at 30°C for 24 h and imaged (right panel). (C) To visualize cell
death, propidium iodide staining was used. C. auris and sensitized C. albicans Tif1L153F were subcultured for 18 h in the absence
or presence of 50 M rocaglate CMLD010515. Cells were pelleted and resuspended in PBS with 1 g/ml propidium iodide. Cells
were imaged by differential interference contrast microscopy and by the use of the DsRed channel on a Zeiss Axio Imager.MI
microscope, with the exposure time remaining constant between samples.
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FIG 4 Rocaglate treatment leads to vacuolar hyperacidification and fragmentation in C. auris. (A) S. cerevisiae heterozygous mutants
with mutations in genes involved in V-ATPase proton pump function are hypersensitive to rocaglates. Strains were grown in YPD in
96-well plates in the absence and presence of 37.5 M CMLD010515, and growth was measured at 48 h. Growth of each strain in the
presence of the rocaglate was plotted relative to growth in a DMSO control. Error bars indicate standard deviations of results of
comparisons between technical triplicates, and a Student’s t test was used to determine if the relative levels of growth of all strains
were significantly different from that seen with the marker matched control (HIS3/his3) (P value of 0.05). (B) Vacuolar pH was
monitored using BCECF-AM, an aciditropic dye which becomes trapped in acidic cellular compartments, resulting in an increase in
fluorescence intensity that correlates with increased pH. Strains were subcultured in YPD medium buffered to pH 5.5 with MES. Cells
were treated with 50 M CMLD010515 for 60 min and then further incubated with 25 g/ml BCECF-AM for 30 min. Cells were washed
and imaged by differential interference contrast microscopy and by the use of the EGFP channel, with the exposure time remaining
(Continued on next page)
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of mitochondrial membrane potential upon rocaglate treatment using both Mito-
Tracker Red, a dye that is irreversibly trapped within the matrix of mitochondria with
intact membrane potential, and the reversible cationic dye tetramethylrhodamine ethyl
ester (TMRE), which accumulates in mitochondria due to their negative charge but is
released upon depolarization. Untreated C. auris and C. albicans Tif1L153F strains dis-
played clear staining of their mitochondria upon incubation with either stain (Fig. 5A;
see also Fig. S5). Upon rocaglate treatment, however, only the C. auris cells failed to
accumulate the dyes in their mitochondria (Fig. 5A; see also Fig. S5), suggesting
rocaglate-induced impairment of C. auris mitochondrial function or integrity. No
changes in dye staining were observed in C. albicans Tif1L153F or C. auris eIF4AL152F
strains treated with CMLD010515. Thus, the rocaglates specifically induced mitochon-
drial dysfunction via translation inhibition in C. auris, consistent with activation of a
species-specific cell death program (Fig. 5A; see also Fig. S5).
Next, we determined whether rocaglate-induced cell death was mediated by cal-
cium signaling, as changes in cytosolic calcium levels have been implicated in trigger-
ing cell death in response to chemical stress (47–49). To address this, we performed
dose-response assays with the rocaglates against C. auris in medium with minimal
levels of calcium (0.68 mM) and with high levels of calcium supplementation (80 mM)
that did not affect growth alone. Although we observed no difference in the levels of
rocaglate-mediated growth inhibition, spotting to assess cidality revealed a greater-
than-4-fold enhancement of rocaglate-mediated cell death in medium supplemented
with calcium (Fig. 5B). This result suggests that altered calcium homeostasis modulates
C. auris cell death in response to rocaglate treatment.
To further characterize the cell death program, we examined caspase-like enzyme
activity and nucleosomal DNA fragmentation. Caspases are classically the major exec-
utors of programmed cell death in mammalian cells, and the yeast metacaspase 1 gene
(MCA1) has been implicated in cell death in S. cerevisiae (22). We engineered a C. auris
mca1mutant but found no change in the level of rocaglate-mediated cidality (Fig. S6A).
Reasoning that an alternative caspase-like activity could be involved, we next took a
biochemical approach and looked for increased cysteine-aspartyl protease activity
upon treatment of C. auris and of rocaglate-sensitized C. albicans Tif1L153F with
CMLD010515 for 18 h. After treatment, the pan-caspase substrate (aspartyl)2-rhod-
amine 110 (D2R) was applied, which, upon proteolytic cleavage within cells, acquires
bright green fluorescence. Propidium iodide was also included to simultaneously
monitor cell viability. Only C. auris cells treated with the rocaglate CMLD010515
demonstrated an increase in either green or red signal, reflecting activation of proteo-
lytic activity or cell death, respectively (Fig. 5C). In addition to the many dead (red) cells
present in the culture, a distinct population of cells was present which exhibited only
green fluorescence, suggesting the induction by rocaglate treatment of proteolytic
activity (either caspase like or potentially vacuolar in origin), which precedes death in
C. auris (50). To complete our survey of apoptotic phenotypes, we assessed whether
rocaglates induce nucleosomal DNA fragmentation in C. auris by the use of a terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay.
Intriguingly, we saw no increase in the number of double-stranded breaks in cells
FIG 4 Legend (Continued)
constant between samples. (C) Vacuolar morphology was visualized using FM4-64 lipophilic dye. Cells were subcultured for 2.5 h, and
then 5 M FM4-64 was added to the cultures for a 30-min incubation. Cells were washed with YPD, resuspended back to original
volume in YPD, and treated with 50 M CMLD010515 for 90 min. Cells were washed 2 and imaged by differential interference
contrast microscopy and by the use of the DsRed channel, with the exposure time remaining constant. Arrows indicate cells with
abnormal vacuolar morphology. (D) The number of yeast cells with one vacuole or abnormal vacuolar morphology was quantified over
two biological replicates, with 100 cells being counted per condition per replicate. Cells with poor staining were classified as
“undetermined.” Averages are graphed with the error bars displaying the standard deviations of results of comparisons between
replicates. t test indicates a significant difference in percentage of cells with abnormal vacuoles in C. auris rocaglate treated samples
relative to the untreated control (*, P  0.0046; n.s., not significant). (E) Transmission electron microscopy was used to visualize
organelle morphology. Cells were subcultured and then treated with 50 M CMLD010515. Cells were fixed at time zero (Untretated),
30 min, and 2 h of treatment for imaging. Identifiable organelles are labeled as follows: V, vacuole; N, nucleus; M, mitochondria; L, lipid
droplet. Arrows indicate sites of vacuolar fragmentation. Scale bars indicate 500 nM for each respective image.
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FIG 5 Sensitive C. auris cells display a loss of mitochondrial membrane potential and increased caspase activity. (A) Loss of mitochondrial
membrane potential was visualized by the use of MitoTracker Red. Cells were subcultured and then treated with 50 M CMLD010515 for 3 h at
30°C with agitation. MitoTracker Red was added to the culture at 50 nM, and the cells were further incubated for 1 h. Cells were imaged by
differential interference contrast microscopy and the use of the DsRed channel on a Zeiss Axio Imager.MI microscope, with the exposure time
remaining constant between samples. (B) The sensitivity of C. auris to the rocaglates in YNB medium containing low calcium levels (0.68 mM) or
excess calcium (80 mM) was assessed by dose-response assays, as described for Fig. 1 (top panel). Cells were taken from the MIC assays, and 5 l
was spotted onto YPD medium without drug. Plates were incubated at 30°C for 24 h and imaged (bottom panel). (C) To detect caspase activity,
a CaspSCREEN assay kit was used. Cells were subcultured for 18 h in the absence or presence of 50 M CMLD010515. Cells were resuspended in
buffer containing the caspase substrate for 45 min. Propidium iodide was added at 1 g/ml to visualize dead cells. Cells were imaged on the EGFP
channel for caspase activity (green) and on the DsRed channel for death (yellow) and by differential interference contrast microscopy on a Zeiss
Axio Imager.MI microscope, all at constant exposure. (D) The rocaglates inhibit translation initiation complex member eIF4A, and the inhibition
is contingent on the presence of specific residues in the drug binding pocket. The inhibition leads to cell death in C. auris, in which phenotypes
such as vacuolar hyperacidification and fragmentation, mitochondrial depolarization, and increased caspase-like activity are observed. In contrast,
rocaglate treatment results in cell arrest in C. albicans in the absence of features of cell death programs.
Rocaglates Induce Cell Death in Candida auris ®
March/April 2020 Volume 11 Issue 2 e03329-19 mbio.asm.org 11
treated with the rocaglates (Fig. S6B). Thus, rocaglate treatment induces a unique form
of programed cell death in C. auris that leads to phenotypes previously linked to
apoptosis in fungi but that is distinct from both traditional apoptosis and autophagy.
DISCUSSION
Upon screening a chemical library of 2,454 compounds, we identified the rocaglates
as a compound class with potent species-selective fungicidal activity against the
emerging multidrug-resistant pathogen C. auris (Fig. 1; see also Fig. 5D). We observed
that rocaglates inhibit translation in C. auris but not in its close pathogenic relative C.
albicans (Fig. 2; see also Fig. 3). The rocaglates have been explored extensively for their
anticancer activity which also results from inhibition of translation, specifically through
the targeting of translation initiation factor eIF4A (37, 51–54). The eIF4A protein is part
of the eIF4F heterotrimeric complex and operates as an RNA helicase that unwinds 5=
untranslated regions (5’UTR) of mRNAs to enable ribosome scanning (55). Rocaglates
enhance the affinity of eIF4A for mRNA, circumventing the requirement for ATP and
resulting in disassociation from the eIF4F complex, as well as sequestering free eIF4As,
which ultimately prevents ribosome scanning (31, 32). All of the rocaglates identified in
our screen were among the strongest enhancers of rocaglate-mediated human eIF4A1-
polypurine RNA clamping reported in a recent study of BU-CMD rocaglates, including
CMLD010515 (RHT) (28) and CMLD010853 (methyl rocaglate) (27). Given the identifi-
cation of eIF4A as the rocaglate target in C. auris, we sought to determine why other
pathogenic fungi were resistant to this compound class. By aligning eIF4A homologs,
we identified residue 153 as divergent between 40 C. albicans isolates and drug-
sensitive fungal and mammalian species (see Fig. S2 in the supplemental material). The
rocaglates bind within a pocket formed by the eIF4A-mRNA interaction. Structurally, the
leucine in C. albicans at position 153 compared to the phenylalanine at the correspond-
ing position in C. auris would be expected to reduce the binding pocket size and impair
compound binding, leading to the inherent resistance observed in C. albicans (30, 32).
This chemostructural finding raises the issue of why C. auris and C. albicans, despite
being related, would be divergent at this residue, leading to inherent resistance of C.
albicans to this natural product.
Another interesting observation from our study is that, despite genetic sensitization
of C. albicans to rocaglate-mediated translation inhibition, sensitization did not lead to
rocaglate-induced cell death such as was observed in C. auris (Fig. 3). One of the
best-established forms of active cell death in yeast is autophagy, a conserved catabolic
process in which the cell digests itself (56). As autophagy can be induced upon
starvation, we hypothesized that translation inhibition could mimic starvation condi-
tions and aberrantly induce autophagy in C. auris, as has been reported in mammalian
cells (57). Upon induction of autophagy, changes in vacuolar morphology occur as
cellular contents are transported to this organelle for degradation (56).To test our
autophagy hypothesis, we investigated vacuolar characteristics and discovered that the
vacuolar compartment became hyperacidified in rocaglate-treated C. auris but not in
the rocaglate-sensitized C. albicans Tif1L153F strain (Fig. 4B; see also Fig. S3A and B).
Hyperacidification could reflect autophagy-associated vacuolar activation, with atten-
dant increases in acidic hydrolase/protease activities, or it could represent a secondary
consequence of the deregulation of other pathways caused by rocaglate-mediated
impairment of protein synthesis. Whatever the mechanism responsible, we did find the
hyperacidified vacuoles in rocaglate-treated C. auris to be fragmented (Fig. 4C and D),
consistent with previous work establishing that vacuolar acidity negatively regulates
vacuolar fusion (44). However, we observed that deletion of genes required for au-
tophagy in S. cerevisiae had no impact on the cidal response to rocaglate treatment
(Fig. S4B). Thus, while autophagy-like phenotypes are observed upon rocaglate treat-
ment, the cell death process triggered by rocaglates does not require the classical
autophagy machinery.
In addition to autophagy, phenotypes considered the hallmarks of metazoan apo-
ptosis have also been reported in fungi. Although the genetic circuitry controlling
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execution of programmed cell responses in fungi remains poorly understood, treat-
ment with H2O2 (22) or amphotericin B (23, 24) was previously shown to induce cell
death, with apoptotic features that included nucleosomal DNA fragmentation, caspase
activation, production of reactive oxygen species (ROS), and mitochondrial depolariza-
tion (15, 16). Consistent with an apoptosis-like cell death program, we observed loss of
mitochondrial membrane potential and increased aspartyl-protease activity in
rocaglate-treated C. auris but not in the sensitized C. albicans Tif1L153F strain (Fig. 5A
and C). Furthermore, we found that the presence of excess extracellular calcium
enhanced the cidality of rocaglates against C. auris (Fig. 5B). This calcium sensitivity is
consistent with previous reports from studies in which increased calcium influx to the
cytosol promoted cell death, specifically by induction of mitochondrial dysfunction (58).
As an atypical feature, however, we did not detect DNA fragmentation in C. auris cells
treated with rocaglates as monitored by TUNEL assay (Fig. S6B), suggesting either that
rocaglates do not induce this classical hallmark of apoptosis in this pathogen or that the
specific assay conditions were not optimal for detecting it.
Overall, our findings indicate that rocaglate-mediated translation inhibition induces
a noncanonical form of programmed cell death in C. auris that has attributes of both
autophagy and apoptosis. A key issue that remains is why translation inhibition triggers
these phenotypes. Autophagic features could be a consequence of misrecognition by
C. auris signaling pathways of stalled translation as a state of amino acid limitation or
pseudostarvation. Phenotypes associated with apoptosis could be a consequence of
translation inhibition causing rapid depletion of one or more short-lived antiapoptotic
proteins which then allows initiation of an active cell death program. Consistent with
this model, the induction of programmed cell death by rocaglates in cancer cells (57,
59, 60) is thought to be driven at least in part by a dramatic reduction in the levels of
short-lived prosurvival proteins such as MCL-1, MDM2, and BCL-xL (59, 61). In certain
malignancies, this proapoptotic effect is amplified by the fact that unlike translation
elongation inhibitors, rocaglates selectively reduce the production of proteins that
require eIF4A for synthesis due to their long, highly structured 5= UTR’s. In mammalian
cells, highly eIF4A-dependent proteins include MYC, MDM2, and cyclins, all of which
promote malignant transformation. Thus, in cancers, rocaglates not only trigger apo-
ptosis but also impair translation of oncogenic drivers (61). In the context of C. auris, it
remains to be explored whether rocaglate-induced cell death is also due to depletion
of specific proteins or if it is attributable more broadly to activation of starvation
responses as a consequence of impaired protein synthesis.
An urgent need to identify vulnerabilities in C. auris exists and is driven by its
extreme resistance to xenobiotic stress. This natural resistance to chemical challenge
could be due to the fact that, unlike other Candida species that are gut colonizers, C.
auris is associated with the skin, where it would be exposed to a plethora of environ-
mental stressors (62). Alternatively, there may be environmental reservoirs of C. auris
where frequent exposure to xenobiotics has selected for the emergence of stress
tolerance and multidrug resistance (63). Here, we report that targeting translation
initiation may provide a strategy to combat this emerging pathogen. The rocaglates
have shown activity against various xenograft tumors in mice (59) and in mouse models
of malaria (64), indicating that the scaffold’s whole-animal pharmacology is compatible
with systemic treatment applications. To fully exploit rocaglates for the treatment of
fungal infections, however, development of a more extensively fungus-selective ana-
logue to avoid host toxicity in the context of acute fungal infections will likely be
required. Despite the inherent challenges with respect to achieving species selectivity,
the rocaglate scaffold is highly tractable to analogue synthesis and precedents exist for
the development of fungus-selective molecules targeting highly conserved cellular
regulators as a powerful approach to combat drug-resistant fungal infections (65, 66).
Given that we found in this study that resistance to the rocaglates was readily acquired
(Fig. 2C), a thorough examination of in vivo efficacy and of the rate at which resistance
emerges in a clinical context should be prioritized with future fungus-selective mole-
cules. Given the limited arsenal of antifungals currently available and the rapid emer-
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gence and spread of drug resistance, it is crucial to pursue development not only of
broad-spectrum antifungals but also of effective strategies for treatment of infections
caused by specific emerging fungal threats.
MATERIALS AND METHODS
Culture conditions. All strains were archived in 25% glycerol in yeast extract-peptone-dextrose
(YPD) medium (1% yeast extract, 2% peptone, and 2% D-glucose) and maintained at 80°C. Strains were
grown either in YPD medium alone or in YPD medium buffered with MES (morpholineethanesulfonic
acid; BioShop), in synthetic defined (SD) medium (0.17% yeast nitrogen base without ammonium sulfate,
0.1% glutamic acid, 2% D-glucose, supplemented with additional histidine-HCl at 20 mg/liter), or in RPMI
medium (10.4 g/liter RPMI 1640, 3.5% MOPS [morpholinepropanesulfonic acid], 2% D-glucose, supple-
mented with additional 5 mg/ml histidine as required, pH 7). All strains, plasmids, and oligonucleotides
used in this study are listed in Tables S1, S2, and S3 in the supplemental material.
BU-CMD library screening conditions. A total of 2,454 diverse compounds from the Boston
University Center for Molecular Discovery (BU-CMD) library were used to identify compounds with
antifungal activity against C. auris. All compounds were dissolved in dimethyl sulfoxide (DMSO) at 5 mM.
RPMI medium was inoculated with 1 103 cells/ml of C. auris (CaLC3438) from a saturated culture.
Medium was dispensed at 100 l per well into 96-well plates. A 1- l volume of DMSO-solubilized
compound from the library was added into each well to reach a final concentration of 50 M. Cells were
incubated for 48 h at 30°C, and the optical density at 600 nm (OD600) was read (Molecular Devices
SpectraMax Plus 384). Percent growth was calculated relative to that seen with the DMSO controls on
each plate. After the initial screen, all secondary chemical susceptibility assays were performed on fresh
sample aliquots that were first assessed for purity by ultraperformance liquid chromatography–mass
spectrometry–evaporative light-scattering detector (UPLC-MS-ELSD) analysis.
Chemical susceptibility assays. Compound potency was assessed by dose-response assays in
96-well, flat-bottom microtiter plates (Sarstedt) or in 384-well, flat-bottom microtiter plates (Corning) as
previously described (67). Plates were incubated at 30°C for the indicated time period. Growth was
quantified by measuring OD600, and the results were corrected for background media. All strains were
assessed in biological-duplicate experiments with technical duplicates. Growth was normalized to the
levels seen with the untreated controls, and data were plotted as a heat map using Java TreeView 1.1.6r4.
Dose-response matrixes (checkerboard assays) were performed in a similar manner except that the
titers of 2-fold serial dilutions of compound 1 (indicated along the x axis of the checkerboard) and
compound 2 (indicated along the y axis) were determined. Values representing the fractional inhibitory
concentration index at 90% growth inhibition (FICI90) were calculated as previously described (68).
BU-CMD hit compounds were newly supplied and dissolved in DMSO, 4EGI-1 (Tocris Biosciences) and
rapamycin (BioShop) were dissolved in DMSO, fluconazole (Sequoia Research Products) was dissolved in
sterile double-distilled water (ddH2O), and calcium chloride (BioShop) was used to supplement yeast
nitrogen base (YNB) media, as indicated.
Cidality assays. Spotting onto drug-free medium was performed to evaluate cidality as previously
described (69). Plates were incubated at 30°C and photographed after 24 h. Propidium iodide staining
was used to visualize cell death. Cells were subcultured from a saturated overnight culture to an OD600
of 0.1 in YPD medium and grown for 18 h in the absence or presence of 50 M CMLD010515. Cells were
pelleted and resuspended in phosphate-buffered saline (PBS) with 1 g/ml propidium iodide. Cells were
imaged by differential interference contrast (DIC) microscopy and by the use of the DsRed channel on
a Zeiss Axio Imager.MI microscope (Carl Zeiss) at the same exposure time.
Fluorescent translation assay. To observe translation in fungal cells, a Click-iT protein synthesis
assay kit (ThermoFisher) was used per the manufacturer’s instructions. Details are provided in Text S1 in
the supplemental material. Cells were imaged by DIC microscopy and by the use of the enhanced green
fluorescent protein (EGFP) channel on a Zeiss Axio Imager.MI microscope (Carl Zeiss) at the same
exposure time.
Selection experiments. To identify mutations conferring resistance to rocaglates, a sensitized C.
auris strain (cdr1o) was used. Four independent lineages were generated. A total of 1 108 cells,
quantified by hemocytometer, from each lineage were plated on YPD agar plates containing 10 M
CMLD010853. Plates were incubated at 30°C until colonies were observed (3 to 5 days). Sanger sequenc-
ing of eIF4A using oligonucleotides oLC7201 to oLC7203 was used to identify mutations.
BCECF-AM and FM4-64 staining and quantification. To observe the pH of yeast vacuoles under
conditions of rocaglate treatment, the cell-permeative aciditrophic dye BCECF-AM (Sigma) was used as
previously described (43). To visualize the vacuolar morphology, the membrane dye FM4-64 was used.
Details are provided in Text S1. Cells were imaged by DIC microscopy or with the DsRed channel or with
the EGFP channel on a Zeiss Axio Imager.MI microscope (Carl Zeiss), with the exposure time remaining
constant between samples of the same species. Brightness was quantified on a CytoFlex flow cytometer
(Beckman) when indicated. The number of yeast cells in each sample with one vacuole or with abnormal
vacuolar morphology was quantified over two biological replicates. Cells with poor staining or that did
not appear within the field of view were classified as undetermined.
Transmission electron microscopy. Transmission electron microscopy was used to visualize organ-
elle morphology. Cells were subcultured to an OD600 of 0.6 in YPD medium at 30°C with agitation and
were then treated with 50 M CMLD010515. The fixation procedure is described in Text S1. Cells were
embedded in the mold at 60°C for 48 h. Cells were sectioned at 90-nm intervals and mounted on a
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200-mesh copper grid. Cells were stained with lead citrate for 5 min and then observed with a Hitachi
Talos L120C transmission electron microscope at 80 kV.
Mitochondrial membrane potential assay. Loss of mitochondrial membrane potential over time
was visualized using MitoTracker Red (Molecular Probes) or the reversible cationic dye tetramethylrho-
damine ethyl ester (TMRE) (Molecular Probes). Details are provided in Text S1. Cells were imaged by DIC
microscopy and by the use of the DsRed (MitoTracker Red) or TexasRed (TMRE) channel on a Zeiss Axio
Imager.MI microscope, with the exposure time remaining constant between samples. For the MitoTracker
Red-treated cells, brightness was also quantified on a CytoFlex flow cytometer (Beckman).
TUNEL assay. DNA fragmentation was visualized using a terminal deoxynucleotidyl transferase
mediated dUTP nick end labeling (TUNEL) assay as previously described (70). Details are provided in Text
S1. Slides were imaged on a Carl Zeiss microscope on the DsRed channel, and cell fluorescence was
quantified by the use of a CytoFlex flow cytometer in the FL2 channel (Ex 561nm/Em 585 nm).
Caspase-like-activity assay. To assess caspase-like proteolytic activity, a CaspSCREEN flow cytometric
apoptosis detection kit (BioVision) was used per the manufacturer’s instructions. Cells were imaged by DIC
microscopy and by the use of the EGFP channel (caspase activity) and the DsRed channel (cell death) on a
Zeiss Axio Imager.MI microscope (Carl Zeiss), with the exposure time remaining constant between all samples.
Flow cytometric analysis for quantification of phenotypes. To quantify various fluorescent
phenotypes, a CytoFlex flow cytometer (Beckman Coulter) was used. In all cases, cells were treated as
described for microscopy above. PBS suspensions were diluted 1:10 in PBS, and 250 l was added to a
flat-bottom transparent 96-well plate (Beckman Coulter). Each sample was run using CytExpert software
until 20,000 events had been documented, populations were gated to exclude debris and doublets,
and the median fluorescein isothiocyanate (FITC) value was taken for each sample to determine the
median brightness of each cell in that sample.
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